GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

A number of ovarian cancer vaccines are being evaluated including the world's first cancer prevention vaccine, which recently ...

Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it. The symptoms ...

Chronic constipation, often dismissed as a minor issue, can sometimes signal serious underlying conditions like colon, rectal ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Study analyzed global patterns and trends in ovarian cancer incidence from 1988 to 2017, highlighting variations by ...

Jayden Whyman met his future wife, Tasha, at a bus stop in Rotorua when they were just teenagers. She loved painting, walking ...

An MRI-based imaging technique developed at the University of Cambridge could be used to predict the response of ovarian ...

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in ...

Tasha Whyman, died in hospice 10 months after being diagnosed with ovarian cancer, her grieving husband and family want ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...